Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | SHFS 0.1324 -61.39% | XXII 0.1977 -8.34% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | RBNE 0.19 -2.56% | YFOR 0.2236 -1.58% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | TQQQ 66.29 -0.20% | TSLL 9.76 -1.21% | VZ 44.66 -1.19% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | GRAB 2.79 -2.11% | AIOK 12.02 182.82% | SQQQ 39.68 0.20% | ONDS 6.2 2.99% | LABT 0.31 -36.67% | AAPL 347.725 -0.14% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | IREN 24.905 -2.37% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | NFLX 65.85 -1.79% | QID 14.55 0.14% | CLRO 3.25 69.27% | WULF 11.32 0.00%
TFTFF Pharmaceuticals, Inc. logo

TFF Pharmaceuticals, Inc. (TFFP)

NASDAQ Global Market · Currency in USD
$0.07 ▼ -0.10 (-60.05%)
At close: Dec 12, 4:00 PM ET. Market closed.
$0.14 ▲ +0.07 (+107.69%)
After hours: Dec 12, 7:59 PM ET

Summary

Previous Close
$0.16
Open
$0.09
Day's Range
$0.06 – $0.09
52 Week Range
$0.06 – $11.00
Volume
11,020,032
Avg. Volume
1,687,665
Market Cap
$288.80K
Beta (5Y Monthly)
1.32
PE Ratio (TTM)
--
EPS (TTM)
-$11.85
Earnings Date
--
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
--

Profile: TFF Pharmaceuticals, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
19
CEO
Harlan F. Weisman

Operating as a clinical-stage biopharmaceutical company, TFF Pharmaceuticals, Inc., leverages its proprietary Thin Film Freezing (TFF) technology platform for the advancement and commercialization of therapeutic products across the United States and Australia. A primary emphasis is placed on creating inhaled dry powder formulations to address various pulmonary ailments and disorders. Its two leading drug candidates, both currently in Phase II clinical trials, include TFF Voriconazole Inhalation Powder, designed to combat invasive pulmonary aspergillosis, and TFF Tacrolimus Inhalation Powder, aimed at preventing lung transplant rejection.

Earnings

DateEst.Actual
Nov 20, 2024-$0.81-$0.81Beat
Aug 14, 2024-$1.70-$1.22Beat
May 14, 2024-$2.20-$2.40Miss
Mar 28, 2024-$2.00-$2.01Miss
Nov 14, 2023-$2.75-$2.25Beat
Aug 15, 2023-$5.00-$3.50Beat

Analyst view

Rating: Buy
Buy 100% · Hold 0% · Sell 0%

Get free alerts on TFFP and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.